IRVING, Texas, May 8, 2026 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State.

Caris Assure is a blood‑based molecular profiling test designed to support comprehensive biomarker analysis using a minimally invasive blood sample. Caris Assure uses circulating nucleic acids sequencing (cNAS) to analyze the whole exome (DNA) and whole transcriptome (RNA) of 22,000 genes. This comprehensive test identifies tumor alterations, clonal hematopoiesis (CH) and inherited variants, pharmacogenomic alterations, microsatellite instability (MSI) and tumor mutational burden (TMB).

The submission initiates the formal review process required by New York State for clinical laboratories seeking to perform testing on specimens collected from New York patients. Through the Wadsworth Center, CLEP conducts comprehensive reviews of laboratory permits and laboratory-developed tests to evaluate analytical validation, quality systems, personnel qualifications and compliance with applicable state regulations.

“Caris is committed to meeting the highest standards for laboratory quality, validation and regulatory compliance,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. “This submission of Caris Assure for review through the New York State Department of Health’s Wadsworth Center reflects our disciplined approach to expanding access to our technologies in a manner that demonstrates the rigor, responsibility and focus on the patient that define Caris Life Sciences and guide our work in the markets we serve.”

At this time, no determination has been made by NYSDOH, and Caris Assure is not authorized for use on blood-based specimens originating from New York State unless and until CLEP authorization is granted.

Caris operates a CAP-accredited, CLIA‑certified clinical laboratory and performs testing in jurisdictions where it is authorized to do so, in accordance with all applicable federal, state, and local regulations. Any future availability of Caris Assure in New York State will be contingent upon completion of the CLEP review process administered by the Wadsworth Center and receipt of the appropriate authorization.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “potential,” “contemplate,” “believe,” “estimate,” “predict,” or “continue” or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-submits-application-to-new-york-state-department-of-health-for-caris-assure-bloodbased-testing-authorization-302767104.html

SOURCE Caris Life Sciences

DOWNERS GROVE, Ill., May 8, 2026 /PRNewswire/ — The Board of Directors of Dover Corporation (NYSE: DOV) today declared a regular quarterly cash dividend of $0.52 (fifty-two cents) per share, payable on June 15, 2026, to shareholders of record as of May 29, 2026.

About Dover:

Dover is a diversified global manufacturer and solutions provider with annual revenue of over $8 billion. We deliver innovative equipment and components, consumable supplies, aftermarket parts, software and digital solutions, and support services through five operating segments: Engineered Products, Clean Energy & Fueling, Imaging & Identification, Pumps & Process Solutions and Climate & Sustainability Technologies. Dover combines global scale with operational agility to lead the markets we serve. Recognized for our entrepreneurial approach for over 70 years, our team of approximately 24,000 employees takes an ownership mindset, collaborating with customers to redefine what’s possible. Headquartered in Downers Grove, Illinois, Dover trades on the New York Stock Exchange under “DOV.” Additional information is available at dovercorporation.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dover-declares-regular-quarterly-cash-dividend-302767309.html

SOURCE Dover

Pillar Accounting & Technology officially launched on May 8, 2026, as a dedicated outsourced accounting and technology advisory firm built to help CPA firms, nonprofits, and growing businesses gain financial clarity, strengthen operations, and scale with confidence.

JACKSONVILLE, Fla., May 8, 2026 /PRNewswire-PRWeb/ —  Pillar Accounting & Technology officially launched today as a dedicated outsourced accounting and technology advisory firm built to help CPA firms, nonprofits, and growing businesses gain financial clarity, strengthen operations, and scale with confidence.

Founded by Shelly Lingor, Pillar was created in response to a growing challenge across the accounting industry: businesses and CPA firms increasingly need strategic, technology-enabled accounting support, but many do not have the internal capacity or infrastructure to build it effectively themselves.

Pillar delivers fully managed accounting ecosystems that combine cloud accounting, technology integration, workflow optimization, and advisory support into one connected system. The firm provides services ranging from day-to-day accounting operations through fractional CFO and strategic advisory support.

“Most businesses don’t need another disconnected service provider. They need a complete accounting system that actually works,” said Lingor. “That means clean books, integrated technology, clear reporting, and people who can help turn financial data into real business decisions.”

Pillar serves four core client groups:

CPA firms seeking outsourced Client Accounting Services (CAS) support without expanding internal headcountNonprofit organizations requiring compliant, specialized financial managementGrowing businesses that have outgrown basic bookkeepingE-commerce and multi-entity businesses in need of stronger operational and financial systems

Unlike traditional outsourced accounting providers, Pillar does not offer tax preparation or wealth management services. That positioning allows the firm to operate as a collaborative, non-competing partner to CPA firms and advisory practices.

The firm’s technology-forward model includes expertise in platforms such as QuickBooks Online, Xero, A2X, Cin7 Core, workflow automation systems, and emerging AI-driven operational tools. Pillar also provides accounting system implementation, workflow design, cloud migrations, secure client data hosting, and ongoing optimization support.

Pillar’s launch comes at a time when many CPA firms are overwhelmed by bookkeeping demands, staffing shortages, and growing client expectations around technology and advisory services.

“We’ve seen firms spend too much time buried in accounting cleanup and operational issues instead of focusing on higher-value advisory work,” Lingor said. “Our role is to remove that burden so firms and business owners can focus on growth, strategy, and serving their clients well.”

The company’s leadership team includes Jay Kimelman, who recently joined the firm as Chief Operating Officer and leads Pillar’s Virtual Chief Technology Officer (VCTO) practice. His background in outsourced accounting, automation, systems integration, and AI-driven workflows strengthens the firm’s operational and technology capabilities.

Pillar’s approach is rooted in what the firm describes as a “no-judgment partnership” philosophy—recognizing that many businesses seeking accounting support are navigating rapid growth, operational complexity, or financial systems that have fallen behind.

“Messy books are usually a symptom of growth without infrastructure,” Lingor said. “We’ve seen this before. Our job is to help clients build the systems and visibility they need moving forward.”

The firm will initially focus on serving clients and partners throughout Florida and Georgia, with a broader nationwide growth strategy centered on CPA firm partnerships and cloud-based service delivery.

For more information, visit pillaraccountingandtechnology.com.

ABOUT PILLAR ACCOUNTING & TECHNOLOGY

Pillar Accounting & Technology is a technology-enabled accounting and advisory firm serving CPA firms, nonprofits, and growing businesses. The firm provides outsourced accounting, cloud accounting systems, and strategic advisory services designed to deliver clean financials, operational clarity, and better business decision-making. Pillar combines integrated technology with expert human support to help clients build scalable accounting systems that grow with their businesses.

Media Contact

Shelly Lingor, Pillar Accounting & Technology, 1 9047549488, slingor@pillaraccts.com, https://pillaraccountingandtechnology.com/

View original content to download multimedia:https://www.prweb.com/releases/pillar-accounting–technology-launches-with-a-tech-driven-complete-system-approach-to-accounting-and-advisory-302767203.html

SOURCE Pillar Accounting & Technology